Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy

অনুরূপ উপাদানগুলি

• Early Initiation of Lopinavir/Ritonavir in Infants Less Than 6 Weeks of Age: Pharmacokinetics and 24 Week Safety and Efficacy
  অনুযায়ী: Chadwick, Ellen Gould, অন্যান্য
  প্রকাশিত: (2009)
• Assessment of Lopinavir Pharmacokinetics With Respect to Developmental Changes in Infants and the Impact on Weight Band–Based Dosing
  অনুযায়ী: Nikanjam, Mina, অন্যান্য
  প্রকাশিত: (2011)
• Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age
  অনুযায়ী: Persaud, Deborah, অন্যান্য
  প্রকাশিত: (2012)
• Pharmacokinetics of High-Dose Lopinavir-Ritonavir with and without Saquinavir or Nonnucleoside Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus-Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors
  অনুযায়ী: Robbins, Brian L., অন্যান্য
  প্রকাশিত: (2008)
• Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development from Infancy through Adulthood
  অনুযায়ী: Yang, Jincheng, অন্যান্য
  প্রকাশিত: (2018)